Lydfilen for denne episode er muligens beskadiget
How to fix it?
OM DENNE EPISODE
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Engelsk
USA
SØK BLANT TIDLIGERE EPISODER
Søk etter gamle episoder av FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
ANDRE EPISODE I DENNE PODKAST
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
Ansvarsfraskrivelse: Podkasten og kunstværket, det finnes indlejret på denne siden, er fra U.S. Food and Drug Administration, Center for Drug Evaluation and Research, som tilhører dens eier og ikke er tilknyttet eller godkjent av Listen Notes, Inc.
REDIG
Takk fordi du hjelper med å holde podkast-databasen oppdatert.
